Bolt Biotherapeutics Inc (BOLT) USD0.00001
Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.